{"result": {"id": "0e761eda-9b10-4c96-adc4-5e63d1d0a0df", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>CTD<|>organization<|>CTD is a connective tissue disease that requires early diagnosis and effective treatment to improve prognosis. It involves treatments like hormones, immunosuppressants, and non-steroidal anti-inflammatory drugs.\")\n##\n(\"entity\"<|>PV<|>organization<|>Polycythemia vera (PV) is a myeloproliferative neoplasm often diagnosed in middle-aged and elderly individuals, associated with JAK2 gene mutation. It causes symptoms like headache, dizziness, and hypertension due to increased blood volume.\")\n##\n(\"entity\"<|>MM<|>organization<|>Multiple myeloma (MM) is a plasma cell malignancy causing bone lesions, kidney disease, and hypertension. It may lead to metabolic abnormalities, kidney damage, and endothelial dysfunction.\")\n##\n(\"entity\"<|>JAK2<|>organization<|>Janus kinase 2 (JAK2) is a gene often mutated in PV, contributing to its pathogenesis.\")\n##\n(\"entity\"<|>RAS INHIBITOR<|>organization<|>RAS inhibitors (ACEI, ARB) are used in treating CTD-related hypertension and may improve endothelial function and inflammation markers.\")\n##\n(\"entity\"<|>ACEI<|>organization<|>Angiotensin-converting enzyme inhibitor (ACEI) is a type of RAS inhibitor used in hypertension management.\")\n##\n(\"entity\"<|>ARB<|>organization<|>Angiotensin receptor blocker (ARB) is a type of RAS inhibitor used in hypertension management.\")\n##\n(\"entity\"<|>CCB<|>organization<|>Calcium channel blocker (CCB) is a class of drugs used to treat hypertension in PV patients.\")\n##\n(\"relationship\"<|>PV<|>JAK2<|>PV is often associated with JAK2 gene mutation<|>8)\n##\n(\"relationship\"<|>MM<|>PV<|>Both MM and PV are hematologic disorders that can cause hypertension<|>4)\n##\n(\"relationship\"<|>CTD<|>RAS INHIBITOR<|>RAS inhibitors are used to treat CTD-related hypertension<|>7)\n##\n(\"relationship\"<|>ACEI<|>ARB<|>Both ACEI and ARB are types of RAS inhibitors used in hypertension treatment<|>6)\n##\n(\"relationship\"<|>PV<|>CCB<|>CCB is used to manage hypertension in PV patients<|>5)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558797, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 538, "prompt_tokens": 2391, "total_tokens": 2929, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1792}, "prompt_cache_hit_tokens": 1792, "prompt_cache_miss_tokens": 599}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 性药物治疗过程中更易发生高血压 ;\n\n\n　同时 ,常伴早发且不能用常规危险因素解释的动脉粥  样硬化及心脑血管疾病 。CTD早期诊断、有效治疗 ,  有望改善预后 。对高血压患者中 CTD易感人群要进  行初步排查 ;一旦高度疑似 CTD,应建议转风湿免疫  专科进行确诊及治疗 。CTD 的专科治疗 ,包括激素、 免疫抑制剂及非甾体抗炎药等针对原发病及对症治  疗 ;而对 CTD相关性高血压的治疗 ,几种常用降压药  均可单用或联合治疗 。有研究结果显示 RAS抑制剂  (ACEI、ARB)对于改善内皮功能、改善炎症指标等具  有潜在益处[742] 。必要时应积极予以他汀类药物及抗  血小板治疗 。有研究显示 , 他汀类药物治疗 CTD 时  可降低胆固醇、减少心血管疾病及全因死亡风险 ,具有  明显临床益处[742] 。\n　10.10  血液疾病与高血压  血液系统导致高血压的 常见疾病有真性红细胞增多症(polycythemia vera, PV) 和多发性骨髓瘤(multiple myeloma,MM) 。\n　　　PV属骨髓增生性肿瘤 。常在中老年期发病 , 大 多与 Janus激酶 2(Januskinase2, JAK2) 基因突变 有关[743] 。 临床特征多有头痛、头晕 ; 多血质、血栓形 成、出血 ;高尿酸血症、脾肿大等 ; 高血压亦是常见症 状 ,与血容量增加有关 ; 同时 ,高血压亦是 PV患者促 血栓形成的危险因素 。 目前 PV诊断标准 :血红蛋白 浓度>16.5 g/dL和红细胞压积>49%(男性) ; 血红\n\n\n\n　蛋白浓度>16.0 g/dL和红细胞压积>48%(女性) ; 骨髓三系增生及 JAK2基因突变为主要诊断标准 ;次 要标准为促红细胞生成素降低[744] 。PV 患者需血液 专科治疗 ,包括放血疗法及以羟基脲为一线药物的骨 髓抑制治疗 ;抗血小板及对症治疗 。高血压控制常用 RAS抑制剂、CCB及其他类降压药 ,但因 PV患者常 发生血栓性疾病及痛风 ,故利尿剂不宜使用。\n　　　MM是一种浆细胞恶性肿瘤 。主要有骨骼病变、 骨髓瘤肾病、高钙血症、贫血、出血等表现 。MM 致血  压升高的可能机制包括代谢异常、肾脏损害、炎症细胞  因子、内皮功能受损等[745-746] 。常用降压药均可用于  MM患者的高血压治疗 ;但因 MM时常伴有高尿酸血  症、高黏滞血�\n######################\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_81452fce521e515ba0fca30fa9d92fe721761f2653c85ef23ebd6fa7a42de444_v2"}